Swiss Biotech Secures Major Funding for Advanced Cancer Treatments
July 12, 2025, 9:43 pm
Swiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will accelerate clinical trials. They will boost manufacturing capabilities. Global expansion is a key objective. Prostate, neuroendocrine, and breast cancers are primary focuses. New board members enhance leadership. Precision oncology takes a leap forward. Patients worldwide stand to benefit.
The Basel-based radiopharmaceutical company, NUCLIDIUM, recently closed its Series B financing round. It raised a substantial €84 million. This funding marks a pivotal moment for the clinical-stage biotech. It validates its innovative approach to cancer care.
A strong syndicate led the round. Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR were key players. Additional participation came from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, and HighLight Capital. Existing investors also contributed. This broad support underscores confidence in NUCLIDIUM’s technology and market potential.
NUCLIDIUM specializes in radiotheranostics. This advanced field combines diagnosis and therapy. The company leverages proprietary copper isotopes. Copper-61 is for diagnostic imaging. Copper-67 is for targeted therapeutic delivery. This dual-isotope platform aims to revolutionize oncology.
The technology offers significant advantages. It seeks to overcome limitations in current radiotheranostics. These include suboptimal clinical efficacy and complex manufacturing processes. NUCLIDIUM’s platform streamlines hospital workflows. It simplifies care delivery. Waste management becomes more efficient. This approach increases accessibility worldwide.
The company's lead compounds are NuriPro™ and TraceNET™. These are currently in clinical development. They target multiple oncology indications. Initial trials show promising results. Diagnostic trials with 61Cu-NuriPro™ demonstrate superior lesion detection. They exhibit higher tumor-to-background ratios. This surpasses current PET imaging standards. Data highlighted a favorable safety profile. The potential for improved imaging performance is clear.
Early therapeutic data also show strong performance. NuriPro™ and TraceNET™ achieve robust tumor-to-background ratios. This is observed in metastatic prostate cancer. They also perform well in neuroendocrine tumors. Breast cancer is another area of focus. NUCLIDIUM commits to addressing unmet medical needs. This includes a strong emphasis on women's health. The flexible copper theranostic platform allows rapid development. It targets new pathways across a wider range of cancers.
The newly secured capital has clear objectives. A primary goal is to accelerate clinical development. This involves advancing the Copper-61/Copper-67 theranostic pipeline. Multiple oncology indications will be explored. Expanding the global production and manufacturing network is another key aim. This ensures broader availability of diagnostics and therapeutics.
NUCLIDIUM will also grow its international team. It will strengthen strategic collaborations. These partnerships will span hospitals and academic centers. Initial expansion targets Europe and North America. This global outreach supports wider patient access.
The Series B financing reinforces NUCLIDIUM’s vision. It positions the company for significant growth. The transformative potential for the diagnostic and therapeutic industry is evident. Nuclear medicine stands to benefit immensely. The backing accelerates clinical progress. It broadens patient reach. It solidifies innovation in precision oncology.
The financing round also brings new expertise to NUCLIDIUM's leadership. Daniel Parera, Partner at Kurma Partners, joins the Board of Directors. Regina Hodits, Managing Director at Angelini Ventures, also takes a seat. Liliana Nordbakk, Partner Life Sciences at Neva SGR, completes the new board additions. Their collective deep expertise will strengthen NUCLIDIUM’s position. It reinforces leadership in radiopharmaceuticals.
NUCLIDIUM's platform stands out. It operates in a rapidly evolving medical field. Its innovation promises to reshape radiotheranostic care delivery. This investment reflects a strong conviction. It signals belief in the future of precision medicine. It shows confidence in NUCLIDIUM’s potential for scale. This ambition is shared across a strong European syndicate of investors.
The company, founded in 2017, continues its pioneering work. Operations in Switzerland and Germany combine vital capabilities. Chemistry expertise is integrated. Deep clinical knowledge is paramount. Strategic manufacturing capabilities ensure scalability. The goal is to deliver accessible and clinically superior theranostic solutions. These solutions aim to reach patients worldwide.
This funding round is more than financial support. It is a testament to scientific advancement. It highlights a commitment to global health. NUCLIDIUM’s copper-based platform offers a new frontier. It provides hope for millions battling cancer. Its potential for transformative impact on healthcare is immense. The journey to more effective cancer treatments continues. This investment fuels that vital progress. Precision oncology moves closer to reality for countless individuals.
The Basel-based radiopharmaceutical company, NUCLIDIUM, recently closed its Series B financing round. It raised a substantial €84 million. This funding marks a pivotal moment for the clinical-stage biotech. It validates its innovative approach to cancer care.
A strong syndicate led the round. Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR were key players. Additional participation came from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, and HighLight Capital. Existing investors also contributed. This broad support underscores confidence in NUCLIDIUM’s technology and market potential.
NUCLIDIUM specializes in radiotheranostics. This advanced field combines diagnosis and therapy. The company leverages proprietary copper isotopes. Copper-61 is for diagnostic imaging. Copper-67 is for targeted therapeutic delivery. This dual-isotope platform aims to revolutionize oncology.
The technology offers significant advantages. It seeks to overcome limitations in current radiotheranostics. These include suboptimal clinical efficacy and complex manufacturing processes. NUCLIDIUM’s platform streamlines hospital workflows. It simplifies care delivery. Waste management becomes more efficient. This approach increases accessibility worldwide.
The company's lead compounds are NuriPro™ and TraceNET™. These are currently in clinical development. They target multiple oncology indications. Initial trials show promising results. Diagnostic trials with 61Cu-NuriPro™ demonstrate superior lesion detection. They exhibit higher tumor-to-background ratios. This surpasses current PET imaging standards. Data highlighted a favorable safety profile. The potential for improved imaging performance is clear.
Early therapeutic data also show strong performance. NuriPro™ and TraceNET™ achieve robust tumor-to-background ratios. This is observed in metastatic prostate cancer. They also perform well in neuroendocrine tumors. Breast cancer is another area of focus. NUCLIDIUM commits to addressing unmet medical needs. This includes a strong emphasis on women's health. The flexible copper theranostic platform allows rapid development. It targets new pathways across a wider range of cancers.
The newly secured capital has clear objectives. A primary goal is to accelerate clinical development. This involves advancing the Copper-61/Copper-67 theranostic pipeline. Multiple oncology indications will be explored. Expanding the global production and manufacturing network is another key aim. This ensures broader availability of diagnostics and therapeutics.
NUCLIDIUM will also grow its international team. It will strengthen strategic collaborations. These partnerships will span hospitals and academic centers. Initial expansion targets Europe and North America. This global outreach supports wider patient access.
The Series B financing reinforces NUCLIDIUM’s vision. It positions the company for significant growth. The transformative potential for the diagnostic and therapeutic industry is evident. Nuclear medicine stands to benefit immensely. The backing accelerates clinical progress. It broadens patient reach. It solidifies innovation in precision oncology.
The financing round also brings new expertise to NUCLIDIUM's leadership. Daniel Parera, Partner at Kurma Partners, joins the Board of Directors. Regina Hodits, Managing Director at Angelini Ventures, also takes a seat. Liliana Nordbakk, Partner Life Sciences at Neva SGR, completes the new board additions. Their collective deep expertise will strengthen NUCLIDIUM’s position. It reinforces leadership in radiopharmaceuticals.
NUCLIDIUM's platform stands out. It operates in a rapidly evolving medical field. Its innovation promises to reshape radiotheranostic care delivery. This investment reflects a strong conviction. It signals belief in the future of precision medicine. It shows confidence in NUCLIDIUM’s potential for scale. This ambition is shared across a strong European syndicate of investors.
The company, founded in 2017, continues its pioneering work. Operations in Switzerland and Germany combine vital capabilities. Chemistry expertise is integrated. Deep clinical knowledge is paramount. Strategic manufacturing capabilities ensure scalability. The goal is to deliver accessible and clinically superior theranostic solutions. These solutions aim to reach patients worldwide.
This funding round is more than financial support. It is a testament to scientific advancement. It highlights a commitment to global health. NUCLIDIUM’s copper-based platform offers a new frontier. It provides hope for millions battling cancer. Its potential for transformative impact on healthcare is immense. The journey to more effective cancer treatments continues. This investment fuels that vital progress. Precision oncology moves closer to reality for countless individuals.